Medpace acquires European CRO
Medpace, a US-based clinical research organisation, is continuing its European expansion with the acquisition of Medical Consulting Dr Schlichtiger.
Medpace, a US-based clinical research organisation, is continuing its European expansion with the acquisition of Medical Consulting Dr Schlichtiger.
Medical Consulting Dr Schlichtiger, based in Munich, Germany, is a CRO with drug development expertise providing customised regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies.
Medpace says Medical Consulting will add "strategic expertise" by providing centralised European hubs for regulatory submissions and approvals as well as drug safety management and reporting.
Ursula Schlichtiger, who leads Medical Consulting as general manager, will join the Medpace team as managing director and senior director of medical and regulatory affairs, Europe.
"Dr Schlichtiger has built a reputation in Europe as a distinguished professional having founded Medical Consulting in 1989 and building the company into an organisation widely recognised for its successful interaction with European governmental agencies," said August Troendle, ceo of Medpace.
The integration process will be completed by June.
Medpace has more than 900 employees and clinical trial experience in 40 countries.